- Home
- CBUS vs ACET Comparison
CBUS vs ACET Comparison
Compare CBUS & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBUS
- ACET
- Stock Information
- Founded
- CBUS 2010
- ACET 1947
- Country
- CBUS United States
- ACET United States
- Employees
- CBUS N/A
- ACET N/A
- Industry
- CBUS Agricultural Chemicals
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- CBUS Industrials
- ACET Health Care
- Exchange
- CBUS Nasdaq
- ACET Nasdaq
- Market Cap
- CBUS 65.3M
- ACET 64.9M
- IPO Year
- CBUS 2017
- ACET N/A
- Fundamental
- Price
- CBUS $1.50
- ACET $0.67
- Analyst Decision
- CBUS Strong Buy
- ACET Buy
- Analyst Count
- CBUS 3
- ACET 6
- Target Price
- CBUS $22.00
- ACET $6.00
- AVG Volume (30 Days)
- CBUS 709.5K
- ACET 412.2K
- Earning Date
- CBUS 08-07-2025
- ACET 08-12-2025
- Dividend Yield
- CBUS N/A
- ACET N/A
- EPS Growth
- CBUS N/A
- ACET N/A
- EPS
- CBUS N/A
- ACET N/A
- Revenue
- CBUS $4,751,000.00
- ACET N/A
- Revenue This Year
- CBUS $32.97
- ACET N/A
- Revenue Next Year
- CBUS $66.40
- ACET N/A
- P/E Ratio
- CBUS N/A
- ACET N/A
- Revenue Growth
- CBUS 104.78
- ACET N/A
- 52 Week Low
- CBUS $1.40
- ACET $0.45
- 52 Week High
- CBUS $10.77
- ACET $1.70
- Technical
- Relative Strength Index (RSI)
- CBUS 37.01
- ACET 43.24
- Support Level
- CBUS $1.40
- ACET $0.72
- Resistance Level
- CBUS $1.58
- ACET $0.84
- Average True Range (ATR)
- CBUS 0.22
- ACET 0.06
- MACD
- CBUS -0.09
- ACET -0.02
- Stochastic Oscillator
- CBUS 5.43
- ACET 0.00
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.